Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, Boyer-Guittaut M, Galaine J, Guenat D, Mougey V, Perrard J, Pallandre J R, Bouard A, Balland J, Tirole C, Adotevi O, Hendrick E, Herfs M, Cartron P F, Borg C, Hervouet E
Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France.
University Hospital of Besançon, Medical Oncology Department, Besançon, France.
Oncoimmunology. 2018 Feb 1;7(5):e1423170. doi: 10.1080/2162402X.2017.1423170. eCollection 2018.
Tumor cells, which undergo Epithelial-mesenchymal transition (EMT) acquire increased capacities of proliferation, invasion and have the ability to generate metastases by escaping the immune system during their systemic migration. To escape the immune system, cancer cells may induce tolerance or resist elimination by immune effectors multiple mechanisms and we hypothesized that EMT may control the expression of immune checkpoint inhibitors, then promoting immune evasion. PD-L1 (programmed cell death ligand 1) but not PD-L2 nor Galectin 9 or Death receptor (DR4, DR5 and Fas) and ligands (FasL and TRAIL) expression was up-regulated during cytokine-driven EMT in a reversible manner. Moreover PD-L1 is overexpressed in VIMENTIN positive NSCLC tissues. We also demonstrated that the expression of PD-L1 required both TNFα and TGFβ1. Indeed, TGFβ1 decreased DNMT1 content and that resulted in promoter demethylation whereas TNFα induced the NF-κB pathway that promoted expression of demethylated promoter.
经历上皮-间质转化(EMT)的肿瘤细胞获得了更强的增殖和侵袭能力,并在全身迁移过程中通过逃避免疫系统而具备产生转移灶的能力。为了逃避免疫系统,癌细胞可能通过多种机制诱导免疫耐受或抵抗免疫效应细胞的清除,我们推测EMT可能控制免疫检查点抑制剂的表达,进而促进免疫逃逸。在细胞因子驱动的EMT过程中,程序性死亡配体1(PD-L1)的表达以可逆的方式上调,而程序性死亡配体2(PD-L2)、半乳糖凝集素9以及死亡受体(DR4、DR5和Fas)及其配体(FasL和肿瘤坏死因子相关凋亡诱导配体)的表达并未上调。此外,波形蛋白阳性的非小细胞肺癌组织中PD-L1过表达。我们还证明,PD-L1的表达需要肿瘤坏死因子α(TNFα)和转化生长因子β1(TGFβ1)。事实上,TGFβ1降低了DNA甲基转移酶1(DNMT1)的含量,导致启动子去甲基化,而TNFα诱导核因子κB(NF-κB)信号通路,促进去甲基化启动子的表达。